Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURAN study of buparlisib (AN2025) + paclitaxel vs paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma
jRCT2011210034Completed
- Sponsor
- Adlai Nortye
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Randomised trial of buparlisib in head and neck squamous cell carcinoma (HNSCC) and metastatic head and neck squamous cell carcinoma (mHNSCC) (2 arms), sponsored by Adlai Nortye. Primary endpoint: Overall survival. Started Jul 2021; status: completed.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)metastatic head and neck squamous cell carcinoma (mHNSCC)
Beyond the preview
Go deeper on jRCT2011210034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210034.